AnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have received a consensus rating of “Moderate Buy” from the eleven research firms that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $51.10.

A number of equities analysts have commented on the stock. Truist Financial lifted their target price on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price target on shares of AnaptysBio in a research report on Wednesday, August 14th. Wedbush reiterated an “outperform” rating and issued a $42.00 price objective on shares of AnaptysBio in a research report on Thursday. Finally, JPMorgan Chase & Co. raised their target price on AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th.

Insider Activity at AnaptysBio

In other news, major shareholder Ecor1 Capital, Llc bought 273,972 shares of the stock in a transaction that occurred on Wednesday, August 14th. The stock was bought at an average cost of $36.50 per share, for a total transaction of $9,999,978.00. Following the acquisition, the insider now directly owns 7,794,996 shares of the company’s stock, valued at approximately $284,517,354. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other AnaptysBio news, CFO Dennis Mulroy sold 12,220 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the completion of the transaction, the chief financial officer now owns 4,744 shares in the company, valued at $189,333.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Ecor1 Capital, Llc acquired 273,972 shares of AnaptysBio stock in a transaction dated Wednesday, August 14th. The stock was bought at an average price of $36.50 per share, for a total transaction of $9,999,978.00. Following the completion of the purchase, the insider now owns 7,794,996 shares of the company’s stock, valued at approximately $284,517,354. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 33,940 shares of company stock worth $1,251,836. 33.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On AnaptysBio

Several large investors have recently bought and sold shares of the stock. Trexquant Investment LP boosted its stake in shares of AnaptysBio by 107.6% in the 4th quarter. Trexquant Investment LP now owns 21,832 shares of the biotechnology company’s stock valued at $468,000 after buying an additional 11,318 shares during the period. Franklin Resources Inc. lifted its stake in AnaptysBio by 22.7% in the fourth quarter. Franklin Resources Inc. now owns 405,115 shares of the biotechnology company’s stock worth $8,678,000 after acquiring an additional 75,025 shares during the last quarter. First Light Asset Management LLC grew its holdings in AnaptysBio by 56.4% during the 4th quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock worth $26,500,000 after acquiring an additional 446,372 shares in the last quarter. Great Point Partners LLC grew its holdings in AnaptysBio by 9.2% during the 4th quarter. Great Point Partners LLC now owns 976,981 shares of the biotechnology company’s stock worth $20,927,000 after acquiring an additional 82,648 shares in the last quarter. Finally, Octagon Capital Advisors LP purchased a new stake in shares of AnaptysBio in the 4th quarter valued at approximately $2,570,000.

AnaptysBio Stock Performance

NASDAQ:ANAB opened at $31.87 on Friday. AnaptysBio has a one year low of $13.36 and a one year high of $41.31. The stock has a market cap of $870.66 million, a PE ratio of -5.19 and a beta of -0.29. The stock has a 50 day moving average price of $35.72 and a 200 day moving average price of $28.09.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). The company had revenue of $10.97 million during the quarter, compared to analyst estimates of $25.85 million. AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. As a group, analysts predict that AnaptysBio will post -6.84 earnings per share for the current fiscal year.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.